MODERN-HEALTH
16.7.2024 08:01:25 CEST | Business Wire | Pressemeddelelse
Modern Health, en førende mental sundhedsplatform på det globale arbejdsmarked og Generali Health Solutions GmbH offentliggør i dag et eksklusivt partnerskab. Som udbyder af bevist effektive sundhedsprogrammer er Generali Health Solutions GmbH en del af den internationale Generali Group, som er en af de største globale udbydere af forsikringer og formueforvaltning. Dette partnerskab kommer på et tidspunkt, hvor der er et stigende behov for support af den mentale sundhed på arbejdspladsen. Depression er den førende årsag til uarbejdsdygtighed i verden med 12 milliarder mistede arbejdsdage pga. depression og angst, hvilket giver et anslået årligt tab i produktivitet på USD 1 billion. Partnerskabet gør det nu muligt for arbejdsgivere i mere end 50 lande at investere i mental sundhed for deres medarbejdere, hvilket er et stort skridt fremad i prioriteringen af mental sundhed på global skala.
“Vi er overbeviste om, at global retfærdighed i mental sundhed skal gå længere end adgang til eller appoversættelser – det skal være en integreret del af hvert enkelt aspekt i omsorg for og afspejling af hver person og deres unikke oplevelser,” siger Alyson Watson, grundlægger og adm. direktør for Modern Health. “Vi sætter enkeltpersoner i centrum for deres mentale sundhedsforløb og sikrer, at mental sundhed føles så personlig som den person, den skal hjælpe. Vi er imponerede over Generalis tilsagn til deres kunder og er beærede over at blive partner for at forbedre livet for mennesker over hele verden med ægte global og personlig mental sundhedsomsorg, der giver de bedste resultater for medlemmer, hvad der behov må være, eller hvor de bor.”
Dette samarbejde giver arbejdsgivere mulighed for nemt at få adgang til Modern Healths omfattende globale mentale sundhedsfordele på det globale arbejdsmarked via Generali Health Solutions. Dette omfatter en-til-en-support fra autoriserede terapeuter og certificerede coaches, gruppefællesskabs Circles, de første i branchen Pathways, krisesupport og en omfattende samling digitale ressourcer via selvbetjening til emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov – alt sammen på en platform. Modern Healths innovative og bæredygtige trindopdelte omsorgsmetode giver en solid, beviselig support for hele den globale arbejdsstyrke, der medfører målbare resultater for alle, lige meget hvad de lever med.
"Vores mål er et give vores kunder innovative løsninger, som fremmer sundhed og modstandsdygtighed på arbejdspladsen og således øge medarbejdernes produktivitet," forklarer Dr. Markus Homann, adm. direktør for Generali Health Solutions. “Vi ved, at der er et stigende behov for velfærdssupport på arbejdspladsen og ved at slå os sammen med Modern Health kan vi nemt og uden problemer forbinde vores kunder til det bedste på markedet for globale mental sundhedspleje.”
Gå til Modern Health eller Generali Health Solutions for at få mere at vide.
Om Modern Health
Modern Health er en omfattende global løsning på mental sundhed, som tilbyder medarbejdere adgang til en-til-en-, gruppe- og selvbetjenings digitale ressourcer til deres emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov - alt på én platform. Når en person ønsker proaktivt at håndtere stress eller behandle depression, guider Modern Health disse mennesker til den rigtige hjælp på det rigtige tidspunkt.
Modern Health støttes af investorer som Kleiner Perkins, Founders Fund, John Doerr, Y Combinator og Battery Ventures og skaffede mere end USD 170 millioner på mindre end to år, hvilket gør Modern Health til det hurtigst helt kvindegrundlagte firma i USA til at nå Unicorn-status.
Om Generali Health Solutions
Generali Health Solutions GmbH (GHS) er en del af den internationale Generali Group. Som udbyder af beviseligt effektive sundhedsprogrammer, som kan bruges i virksomheder, forsikringsselskaber og andre institutioner, skaber GHS primært løsninger, som hjælper medarbejdere med at fortsætte med at være produktive og mere tilfredse. Derudover er målet at reducere produktivitetstab og behandlingsomkostninger pga. Sygdom.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240716732760/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum